Andros Pharmaceuticals Co., Ltd. (6917) Stock Statistics & Valuation Metrics
Total Valuation
Andros Pharmaceuticals Co., Ltd. has a market cap or net worth of TWD 1.65B. The enterprise value is ―.
- Market Cap
- TWD 1.65B
- Enterprise Value
- ―
Share Statistics
Andros Pharmaceuticals Co., Ltd. has 55,272,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 55,272,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Andros Pharmaceuticals Co., Ltd.’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -14.09%.
- Return on Equity (ROE)
- -0.10
- Return on Assets (ROA)
- -0.10
- Return on Invested Capital (ROIC)
- -14.09%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 369.87K
- Profits Per Employee
- -3.59M
- Employee Count
- 15
- Asset Turnover
- 0.01
- Inventory Turnover
- 6.85
Valuation Ratios
The current PE Ratio of Andros Pharmaceuticals Co., Ltd. is -48.41. Andros Pharmaceuticals Co., Ltd.’s PEG ratio is -0.48.
- PE Ratio
- -48.41
- PS Ratio
- 148.11
- PB Ratio
- 3.44
- Price to FCF
- -76.15
- Price to Operating Cash Flow
- -76.34
- PEG Ratio
- -0.48
Income Statement
In the last 12 months, Andros Pharmaceuticals Co., Ltd. had revenue of 5.55M and earned -53.78M in profits. Earnings per share was -1.16.
- Revenue
- 5.55M
- Gross Profit
- -4.96M
- Operating Income
- -75.64M
- Pretax Income
- -53.52M
- Net Income
- -53.78M
- EBITDA
- -68.87M
- Earnings Per Share (EPS)
- -1.16
Cash Flow
In the last 12 months, operating cash flow was -21.91M and capital expenditures -114,000, giving a free cash flow of -22.02M billion.
- Operating Cash Flow
- -21.91M
- Free Cash Flow
- -22.02M
- Free Cash Flow per Share
- -0.40
Dividends & Yields
Andros Pharmaceuticals Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.30%
- Earnings Yield
- -1.98%
Stock Price Statistics
- Beta
- 0.07
- 52-Week Price Change
- 29.57%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 33.08
- Average Volume (3m)
- 426.09K
Financial Position
Andros Pharmaceuticals Co., Ltd. as a current ratio of 13.97, with Debt / Equity ratio of 3.27%
- Current Ratio
- 13.97
- Quick Ratio
- 13.91
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.54
- Interest Coverage Ratio
- -279.10
Taxes
In the past 12 months, Andros Pharmaceuticals Co., Ltd. has paid 251.00K in taxes.
- Income Tax
- 251.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Andros Pharmaceuticals Co., Ltd. EV to EBITDA ratio is -26.24, with an EV/FCF ratio of -75.91.
- EV to Sales
- 147.66
- EV to EBITDA
- -26.24
- EV to Free Cash Flow
- -75.91
- EV to Operating Cash Flow
- -76.31
Balance Sheet
Andros Pharmaceuticals Co., Ltd. has TWD 333.82M in cash and marketable securities with TWD 15.06M in debt, giving a net cash position of TWD 318.76M billion.
- Cash & Marketable Securities
- TWD 333.82M
- Total Debt
- TWD 15.06M
- Net Cash
- TWD 318.76M
- Net Cash Per Share
- TWD 5.77
- Tangible Book Value Per Share
- TWD 8.86
Margins
Gross margin is -27.74%, with operating margin of -625.22%, and net profit margin of -294.63%.
- Gross Margin
- -27.74%
- Operating Margin
- -625.22%
- Pretax Margin
- -292.41%
- Net Profit Margin
- -294.63%
- EBITDA Margin
- -562.78%
- EBIT Margin
- -625.22%
Analyst Forecast
The average price target for Andros Pharmaceuticals Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 5765.28%
- EPS Growth Forecast
- 68.25%
